High Court Finds Drugmaker’s Inducement Claims Fail, Reverses Federal Circuit
WASHINGTON, D.C. — A unanimous U.S. Supreme Court on June 4 held that a biopharmaceutical company failed to plausibly allege that a bioequivalent maker actively induced patent infringement after considering arguments...To view the full article, register now.
Already a subscriber? Click here to view full article